Search

Your search keyword '"Garassino M"' showing total 412 results
Start Over Author "Garassino M"
412 results on '"Garassino M"'

101. P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases

Author

Crinò, L., primary, Bidoli, P., additional, Ulivi, P., additional, Minenza, E., additional, Cortesi, E., additional, Garassino, M., additional, Cappuzzo, F., additional, Grossi, F., additional, Tonini, G., additional, Sarobba, M.G., additional, Pinotti, G., additional, Numico, G., additional, Samaritani, R., additional, Ciuffreda, L., additional, Frassoldati, A., additional, Bregni, M.B., additional, Santo, A., additional, Piantedosi, F., additional, Illiano, A., additional, De Marinis, F., additional, and Delmonte, A., additional

Published
2017
Full Text
View/download PDF

102. P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors

Author

Tessari, A., primary, Palmieri, D., additional, Pawlikowski, M., additional, Parbhoo, K., additional, Foray, C., additional, Fassan, M., additional, La Perle, K., additional, Rulli, E., additional, Fabbri, A., additional, Ganzinelli, M., additional, Embrione, V., additional, Broggini, M., additional, Amann, J., additional, Carbone, D., additional, Garassino, M., additional, Croce, C., additional, and Coppola, V., additional

Published
2017
Full Text
View/download PDF

104. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers

Author

La Verde N, Collovà E, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, Cinquini M, Garassino M, La Verde, N, Collovà, E, Lonardi, S, Generali, D, Moretti, A, Atzori, F, Cazzaniga, M, Saggia, C, Tondulli, L, Marcon, I, Gentile, A, Rossello, R, Martelli, O, Aglione, S, Farina, G, Cinquini, M, and Garassino, M

Subjects
breast cancer
Abstract

Aims and background. We report a collection of data about early breast cancer in male patients from 13 Italian institutions. Methods and study design. We obtained data from patient charts and performed statistical analysis. The primary end points were overall survival and disease-free survival. Results. A total of 205 men with invasive breast cancer was identified, with a median age of 66 years. Pathological characteristics were heterogeneous for T stage, N stage and HER2 status. Histological subtype was predominantly ductal infiltrating carcinoma. Most of them were hormone receptor positive. Mastectomy was the most common strategy. Postsurgical treatment was not standardized. Patients with large tumors were more likely to be treated with chemotherapy. Disease recurrence was associated with an ER+ and PR+ status. Conclusions. We identified a correlation between relapse and hormone receptor expression, as is the case in female breast cancer.

Published
2013

105. ALK gene copy number gains in non-small-cell lung cancer: Prognostic impact and clinico-pathological correlations

Author

Peretti, U., Ferrara, R., Pilotto, S., Kinspergher, S., Caccese, M., Santo, A., Brunelli, M., Caliò, A., Carbognin, L., Sperduti, I., Garassino, M., Chilosi, M., Scarpa, A., Tortora, Giampaolo, Bria, Emilio, Bria, E. (ORCID:0000-0002-2333-704X), Peretti, U., Ferrara, R., Pilotto, S., Kinspergher, S., Caccese, M., Santo, A., Brunelli, M., Caliò, A., Carbognin, L., Sperduti, I., Garassino, M., Chilosi, M., Scarpa, A., Tortora, Giampaolo, Bria, Emilio, and Bria, E. (ORCID:0000-0002-2333-704X)

Abstract

Background: The correlation between ALK gene copy number gain (ALK-CNG) and prognosis in the context of advanced non-small-cell lung cancer (NSCLC) remains a controversial issue. This study aimed to evaluate the association among ALK-CNG according to Fluorescent In Situ Hybridization (FISH), clinical characteristics and survival in resectable and advanced NSCLC. Methods: Clinical and pathological data of patients with resectable and advanced NSCLC were retrospectively collected. Tumor tissues were analyzed for ALK-CNG by FISH, and patients were divided in 3 groups/patterns on the basis of ALK signals: disomic [Pattern A], 3-7 signals [Pattern B], >7 signals [Pattern C]. The association between clinical and pathological features and ALK-CNG patterns was evaluated. Disease/progression-free and overall survival (DFS/PFS and OS) were estimated using the Kaplan-Meyer method. Results: A number of 128 (76.6 %) out of the 167 eligible patients were evaluable for ALK-CNG, displaying pattern A, B and C in 71 (42.5 %), 42 (25.1 %) and 15 (9 %) patients, respectively. Gains in ALK-CNG appear to be more frequent in smokers/former smokers than in non-smokers (74.2 % versus 20.4 %, respectively, p = 0.03). Pattern A and C seem more frequently associated with higher T-stage (T3-4), while pattern B appears more represented in lower T-stage (T 1-2) (p = 0.06). No significant differences in survival rate were observed among the above groups. Conclusions: A high ALK-CNG pattern might be associated with smoking status and theoretically it might mirror genomic instability. The implications for prognosis should be prospectively investigated and validated in larger patients' series. Trial registration: We confirm that all the study was performed in accordance with relevant guidelines and regulations and that all the protocol (part of a larger project MFAG 2013 N.14282) was approved by the local Ethics Committee of the Azienda Ospedaliera Universitaria Integrata of Verona on November 11st

Published
2016

106. Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan

Author

Agustoni, F., primary, Fucà, G., additional, Corrao, G., additional, Vernieri, C., additional, Cavalieri, S., additional, Raimondi, A., additional, Peverelli, G., additional, Prisciandaro, M., additional, Indelicato, P., additional, Dotti, K., additional, Morano, F., additional, Russo, G.L.o., additional, Signorelli, D., additional, Proto, C., additional, Vitali, M., additional, Imbimbo, M., additional, Zilembo, N., additional, Garassino, M., additional, De Braud, F.G.M., additional, and Platania, M., additional

Published
2016
Full Text
View/download PDF

107. Patient-centred approach in a multicenter national study (E-Lung): 405 lung cancer patients and caregivers, nurses and oncologists compared

Author

Torta, R., primary, Ieraci, V., additional, Miniotti, M., additional, Leombruni, P., additional, Airoldi, M., additional, Tiseo, M., additional, Cortesi, E., additional, de Braud, F., additional, Garassino, M., additional, Fasola, G., additional, Iacono, C., additional, Morabito, A., additional, Cascinu, S., additional, and Berardi, R., additional

Published
2016
Full Text
View/download PDF

108. SMO mutations role in malignant pleural mesothelioma: a negative prognostic factor, but possible new target?

Author

Proto, C., primary, Ganzinelli, M., additional, Botta, L., additional, Tiseo, M., additional, Pasello, G., additional, Fabbri, A., additional, Lo Russo, G., additional, Trama, A., additional, Imbimbo, M., additional, Vitali, M., additional, Macerelli, M., additional, Zilembo, N., additional, Gallucci, R., additional, Brissa, A., additional, Platania, M., additional, Zaffaroni, N., additional, Serafini, M.S., additional, De Braud, F., additional, Garassino, M., additional, and Signorelli, D., additional

Published
2016
Full Text
View/download PDF

109. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging

Author

Cavalieri, S., primary, Raimondi, A., additional, Morelli, D., additional, Martinetti, A., additional, de Braud, F., additional, Agustoni, F., additional, Dotti, K., additional, Galli, G., additional, Vernieri, C., additional, Fucà, G., additional, Peverelli, G., additional, Prisciandaro, M., additional, Nichetti, F., additional, Indelicato, P., additional, Lo Russo, G., additional, Prinzi, N., additional, Garassino, M., additional, and Platania, M., additional

Published
2016
Full Text
View/download PDF

110. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Author

Peretti, U., primary, Ferrara, R., additional, Pilotto, S., additional, Kinspergher, S., additional, Caccese, M., additional, Santo, A., additional, Brunelli, M., additional, Caliò, A., additional, Carbognin, L., additional, Sperduti, I., additional, Garassino, M., additional, Chilosi, M., additional, Scarpa, A., additional, Tortora, G., additional, and Bria, E., additional

Published
2016
Full Text
View/download PDF

113. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

Author

Besse, B., primary, Johnson, M., additional, Janne, P.A., additional, Garassino, M., additional, Eberhardt, W.E.E., additional, Besse, B., additional, Peters, S., additional, Toh, C.K., additional, Kurata, T., additional, Li, Z., additional, Kowanetz, M., additional, Mocci, S., additional, Sandler, A., additional, and Rizvi, N.A., additional

Published
2015
Full Text
View/download PDF

116. Maintenance therapy in NSCLC: why? To whom? Which agent?

Author

Novello, S, Milella, M, Tiseo, M, Banna, G, Cortinovis, D, Di Maio, M, Garassino, M, Maione, P, Martelli, O, Vavalà, T, Bria, E, Novello, S, Milella, M, Tiseo, M, Banna, G, Cortinovis, D, Di Maio, M, Garassino, M, Maione, P, Martelli, O, Vavalà, T, and Bria, E

Abstract

Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell lung cancer (NSCLC). Initial trials addressing the question of duration of combination chemotherapy failed to show any overall survival benefit for the prolonged administration over a fixed number of cycles with an increased risk for cumulative toxicity. Nowadays several agents with different ways of administration and a different pattern of toxicity have been formally investigated in the maintenance setting. Maintenance strategies include continuing with an agent already present in the induction regimen or switching to a different one. Taking into consideration that no comparative trials of maintenance with different chemotherapy drugs or targeted agents have been conducted, the choice and the duration of maintenance agents is largely empirical. Furthermore, it is still unknown and it remains an open question if this approach needs to be proposed to every patient in the case of partial/complete response or stable disease after the induction therapy. Here, we critically review available data on maintenance treatment, discussing the possibility to tailor the right treatment to the right patient, in an attempt to optimize costs and benefits of an ever-growing panel of different treatment options.

Published
2011

122. Diagnostics

Author

Einert, T. R., primary, Schmidt, G., additional, Binnig, G., additional, Balacescu, O., additional, Balacescu, L., additional, Rus, M., additional, Buiga, R., additional, Tudoran, O., additional, Todor, N., additional, Nagy, V., additional, Irimie, A., additional, Neagoe, I., additional, Yacobi, R., additional, Ustaev, E., additional, Berger, R. R., additional, Barshack, I., additional, Kaur, K., additional, Henderson, S., additional, Cutts, A., additional, Domingo, E., additional, Woods, J., additional, Motley, C., additional, Dougherty, B., additional, Middleton, M., additional, Hassan, B., additional, Wang, Y., additional, Beasley, E., additional, Naley, M., additional, Schuh, A., additional, Tomlinson, I., additional, Taylor, J., additional, Planchard, D., additional, Lueza, B., additional, Rahal, A., additional, Lacroix, L., additional, Ngocamus, M., additional, Auger, N., additional, Saulnier, P., additional, Dorfmuller, P., additional, Le Chevalier, T., additional, Celebic, A., additional, Pignon, J. P., additional, Soria, J. C., additional, Besse, B., additional, Sun, Y. H., additional, Wang, R., additional, Li, C. G., additional, Pan, Y. J., additional, Chen, H. Q., additional, Chouchane, L., additional, Shan, J., additional, Kizhakayil, D., additional, Aigha, I., additional, Dsouza, S., additional, Noureddine, B., additional, Gabbouj, S., additional, Mathew, R., additional, Hassen, E., additional, Shan, S., additional, al-Rumaihi, K., additional, al-Bozom, I., additional, al-Said, S., additional, Rabah, D., additional, Farhat, K., additional, Jakobsen Falk, I. A., additional, Green, K. H. Z., additional, Lotfi, K., additional, Fyrberg, A., additional, Pejovic, T., additional, Li, H., additional, Mhawech-Fauceglia, P., additional, Hoatlin, M., additional, Guo, M. G., additional, Huang, M., additional, Ge, Y., additional, Hess, K., additional, Wei, C., additional, Zhang, W., additional, Bogush, T. A., additional, Dudko, E. A., additional, Nureev, M. V., additional, Kamensky, A. A., additional, Polotsky, B. E., additional, Tjulandin, S. A., additional, Davydov, M. I., additional, Caballero, M., additional, Hasmats, J., additional, Green, H., additional, Quanz, M., additional, Buhler, C., additional, Sun, J. S., additional, Dutreix, M., additional, Cebotaru, C. L., additional, Placintar, A. N., additional, Ghilezan, N., additional, Balogh, Z. B., additional, Reiniger, L., additional, Rajnai, H., additional, Csomor, J., additional, Szepesi, A., additional, Balogh, A., additional, Deak, L., additional, Gagyi, E., additional, Bodor, C., additional, Matolcsy, A., additional, Bozhenko, V. K., additional, Rozhkova, N. I., additional, Kudinova, E. A., additional, Bliznyukov, O. P., additional, Vaskevich, E. N., additional, Trotsenko, I. D., additional, Kharchenko, N. V., additional, Kiandarian, I. V., additional, Pulito, C., additional, Terrenato, I., additional, Sacconi, A., additional, Biagioni, F., additional, Mottolese, M., additional, Blandino, G., additional, Muti, P., additional, Falvo, E., additional, Strano, S., additional, Mori, F., additional, Ganci, F., additional, Covello, R., additional, Zoccali, C., additional, Biagini, R., additional, Palmer, G. A., additional, Wegdam, W., additional, Meijer, D., additional, Kramer, G., additional, Langridge, J., additional, Moerland, P. D., additional, de Jong, S. M., additional, Vissers, J. P., additional, Kenter, G. G., additional, Buist, M. R., additional, Aerts, J. M. F. G., additional, Milione, M., additional, de Braud, F., additional, Buzzoni, R., additional, Pusceddu, S., additional, Mazzaferro, V., additional, Damato, A., additional, Pelosi, G., additional, Garassino, M., additional, Broggini, M., additional, Marabese, M., additional, Veronese, S., additional, Ganzinelli, M., additional, Martelli, O., additional, Bossel, N., additional, Fontemaggi, G., additional, Manciocco, V., additional, Sperduti, I., additional, Strigari, L., additional, Spriano, G., additional, Domany, E., additional, Donzelli, S., additional, Bellissimo, T., additional, Alessandrini, G., additional, Carosi, M. A., additional, Pescarmona, E., additional, Facciolo, F., additional, Telera, S., additional, Pompili, A., additional, de Vriendt, V., additional, de Roock, W., additional, di Narzo, A. F., additional, Tian, S., additional, Biesmans, B., additional, Jacobs, B., additional, de Schutter, J., additional, Budzinska, E., additional, Sagaert, X., additional, Delorenzi, M., additional, Simon, I., additional, Tejpar, S., additional, Zhu, Y., additional, Wang, H. K., additional, Ye, D. W., additional, Denisov, E., additional, Tsyganov, M., additional, Tashireva, L., additional, Zavyalova, M., additional, Perelmuter, V., additional, Cherdyntseva, N., additional, Kim, Y. C., additional, Jang, T., additional, Oh, I. J., additional, Kim, K. S., additional, Ban, H., additional, Na, K. J., additional, Ahn, S. J., additional, Kang, H., additional, Kim, W. J., additional, Park, C., additional, Abousamra, N. K., additional, El-Din, M. S., additional, and Azmy, E. A., additional

Published
2012
Full Text
View/download PDF

125. Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEUROPAIN-01).

Author

Garassino, M. C., primary, Bianchi, A., additional, Febbraro, A., additional, Spagnoletti, I., additional, Iorno, V., additional, Bramati, A., additional, Carbone, C., additional, Isa, L., additional, Breda, E., additional, Magarotto, R., additional, Torri, V., additional, and Farina, G., additional

Published
2011
Full Text
View/download PDF

139. STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines

Author

Proto, C., Manglaviti, S., Lo Russo, G., Musca, M., Galli, G., Imbimbo, M., Perrino, M., Cordua, N., Rulli, E., Ballatore, Z., Maso, A. Dal, Chella, A., Sbrana, A., Prelaj, A., Ferrara, R., Occhipinti, M., Brambilla, M., De Toma, A., Mazzeo, L., Beninato, T., Signorelli, D., Massa, G., Greco, F.G., Calareso, G., Miliziano, D., Di Mauro, R.M., Mella, G., Lucarelli, A., Paggio, A., Galli, F., Torri, V., de Braud, F.G.M., Pasello, G., Petrini, I., Berardi, R., Ganzinelli, M., Garassino, M., and Zucali, P.

Abstract

Thymic malignancies are rare tumors with few therapeutic options. The STYLE trial was aimed to evaluate activity and safety of sunitinib in advanced/recurrent type B3 thymoma (T) and thymic carcinoma (TC).

Published
2023
Full Text
View/download PDF

140. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

Author

La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G, La Verde, Nicla, Bareggi, Claudia, Garassino, Marina, Borgonovo, Karen, Sburlati, Paola, Pedretti, Donata, and Bianchi, Celso

Abstract

Goals Of the Work: Osteonecrosis of the jaw (ONJ) is a severe complication of bisphosphonates treatment. Bisphosphonates reduce skeletal adverse events and give a clinical benefit to cancer patients. Therefore, it is necessary to identify appropriate procedures to reduce ONJ injures by using a successful monitoring program. In a retrospective study we analyzed the impact of a prevention program based on clinical oral cavity examination, dentists, and patients' education. The aim of the study was to evaluate if this approach might improve ONJ outcome in patients receiving pamidronate or zoledronate.Materials and Methods: We analyzed retrospectively two different groups of patients treated at our Institution: patients treated from October 2003 to June 2005 (group A) and patients treated from June 2005 to April 2007 (group B). In June 2005 the prevention program started for all our patients.Main Results: One hundred and eighty-six cancer patients with bone involvement, treated with bisphosphonates, were considered. Sixteen of them developed ONJ: eight before and eight after June 2005. We observed a consistent difference in the evolution of the two groups. In the first group, four patients underwent a major surgery (one partial maxillectomy, complicated by septic shock and oronasal communication; two partial mandibulectomies; and one segmental mandibular resection), with an important impairment of their quality of life; while the eight new ONJ cases, diagnosed after June 2005, were successfully treated without aggressive dental interventions, and achieved a good control of symptoms.Conclusions: Bisphosphonates-related ONJ is a frequent adverse event (8.6%). The monitoring program proved very efficient to improve the clinical outcome of ONJ, avoiding an aggressive treatment and using a conservative approach and medical therapy. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

141. Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

Author

Broggini M, Garassino MC, and Damia G

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Massimo Broggini,1 Marina Chiara Garassino,2 Giovanna Damia11Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri", 2Division of Medical Oncology, Fondazione IRCCS National Cancer Institute, Milan, ItalyAbstract: Tivantinib is a selective, oral, non-ATP-competitive, small molecule inhibitor of the c-Met receptor, tyrosine kinase, which is implicated at different levels of tumor cell migration, invasion, proliferation, and metastasis. Tivantinib has shown antitumor activity in various human tumor cell lines and in xenograft models of human cancers, including non-small-cell lung cancer. Few therapeutic options are available at present for advanced non-small-cell lung cancer, so there is a pressing need for new therapeutic strategies to improve response and survival. Amplification of Met has been reported in more than 20% of lung tumors that have acquired resistance to epidermal growth factor receptor inhibitors, implying that treatment of these tumors with a c-Met inhibitor should overcome resistance. Tivantinib has shown interesting and promising results in advanced non-small-cell lung cancer and appears to be well tolerated, either alone or in combination with other drugs. An interesting additional feature is the ability of the drug to delay development of new metastasis, in agreement with the proposed role of Met in this particular setting.Keywords: non-small-cell lung cancer, Met inhibitors, tivantinib, biomarkers

Published
2013

148. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.

Author

Reck, M., Carbone, D.P., Garassino, M., and Barlesi, F.

Subjects
*NON-small-cell lung carcinoma, *GENETIC mutation, *ADENOCARCINOMA, *ONCOGENES, *CANCER treatment
Abstract

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of RAS mutations observed in human cancers and is present in 35% of lung adenocarcinomas (LUADs). While the use of targeted therapies and immune checkpoint inhibitors (CPIs) has drastically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC) in recent years, historic attempts to target KRAS (both direct and indirect approaches) have had little success, and no KRAS- specific targeted therapies have been approved to date for patients in this molecular subset of NSCLC. With the discovery by Ostrem, Shokat, and colleagues of the switch II pocket on the surface of the active and inactive forms of KRAS, we now have an improved understanding of the complex interactions involved in the RAS family of signaling proteins which has led to the development of a number of promising direct KRASG12C inhibitors, such as sotorasib and adagrasib. In previously treated patients with KRAS G12C -mutant NSCLC, clinical activity has been shown for both sotorasib and adagrasib monotherapy; these data suggest promising new treatment options are on the horizon. With the stage now set for a new era in the treatment of KRAS G12C -mutated NSCLC, many questions remain to be answered in order to further elucidate the mechanisms of resistance, how best to use combination strategies, and if KRASG12C inhibitors will have suitable activity in earlier lines of therapy for patients with advanced/metastatic NSCLC. • Better understanding of RAS signaling has led to the development of promising directly blocking compounds in KRAS -mutant tumors. • New drug candidates take advantage of the increased knowledge of the KRAS mutation complex and relevant protein structures. • Increasing evidence continues to demonstrate the genomic heterogeneity in KRAS -mutated NSCLC. • Current efforts include understanding and overcoming resistance after treatment with KRASG12C inhibitors. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results